论文部分内容阅读
抗生素相关性腹泻(AAD)是用抗生素常见的并发症,约占3.2％～29％。难辨性梭状芽胞杆菌(cd)占AAD检出致病菌中的25％～30％,病原菌还有沙门菌、白色念珠菌及产肠毒素的产气荚膜梭状芽胞杆菌,但大部分AAD的病原还不明。致AAD最常见的广谱抗生素是攻击肠菌群中的厌氧菌者,以用β-内酰胺抗生素发病率最高。boulardii酵母菌(sb)是欧洲用于抗腹泻的非致病酵母菌,能有效地治疗cd、结肠炎。作者用sb进行双盲、安慰剂对照试验,观察其对接受β-内酰胺抗生素患者的AAD的预防作用。 材料与方法 相继接受口服或静注至少一种广谱青霉素类或头孢菌素的成年住院病人,归于sb(1g,含3×10~(10)CFu/d)或安慰剂组。实
Antibiotic-associated diarrhea (AAD) is a common complication of antibiotics, accounting for about 3.2% to 29%. Clostridium difficile (CD) accounts for 25% to 30% of AAD-detected pathogens, Salmonella, Candida albicans and Enterotoxigenic Clostridium perfringens, but large Part of the pathogen of AAD is unknown. The most common broad-spectrum antibiotics that cause AAD are those that attack anaerobic bacteria in the gut flora to maximize the incidence of beta-lactam antibiotics. The boulardii yeast (sb) is a non-pathogenic yeast used in Europe for anti-diarrhea and is effective in the treatment of cd and colitis. The authors used sb double-blind, placebo-controlled trial to observe its prophylactic effect on AAD in patients receiving β-lactam antibiotics. Materials and Methods Adult inpatients who received oral or intravenous injections of at least one broad spectrum of penicillins or cephalosporins were assigned to either sb (1 g with 3 × 10 10 CFU / day) or placebo. real